Literature DB >> 32563573

Predictors of nonuse of donation after circulatory death lung allografts.

Ashley Y Choi1, Oliver K Jawitz2, Vignesh Raman2, Michael S Mulvihill2, Samantha E Halpern3, Yaron D Barac4, Jacob A Klapper2, Matthew G Hartwig2.   

Abstract

OBJECTIVE: Despite growing evidence of comparable outcomes in recipients of donation after circulatory death and donation after brain death donor lungs, donation after circulatory death allografts continue to be underused nationally. We examined predictors of nonuse.
METHODS: All donors who donated at least 1 organ for transplantation between 2005 and 2019 were identified in the United Network for Organ Sharing registry and stratified by donation type. The primary outcome of interest was use of pulmonary allografts. Organ disposition and refusal reasons were evaluated. Multivariable regression modeling was used to assess the relationship between donor factors and use.
RESULTS: A total of 15,458 donation after circulatory death donors met inclusion criteria. Of 30,916 lungs, 3.7% (1158) were used for transplantation and 72.8% were discarded primarily due to poor organ function. Consent was not requested in 8.4% of donation after circulatory death offers with donation after circulatory death being the leading reason (73.4%). Nonuse was associated with smoking history (P < .001), clinical infection with a blood source (12% vs 7.4%, P = .001), and lower PaO2/FiO2 ratio (median 230 vs 423, P < .001). In multivariable regression, those with PaO2/FiO2 ratio less than 250 were least likely to be transplanted (adjusted odds ratio, 0.03; P < .001), followed by cigarette use (0.28, P < .001), and donor age >50 (0.75, P = .031). Recent transplant era was associated with significantly increased use (adjusted odds ratio, 2.28; P < .001).
CONCLUSIONS: Nontransplantation of donation after circulatory death lungs was associated with potentially modifiable predonation factors, including organ procurement organizations' consenting behavior, and donor factors, including hypoxemia. Interventions to increase consent and standardize donation after circulatory death donor management, including selective use of ex vivo lung perfusion in the setting of hypoxemia, may increase use and the donor pool.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  donation after circulatory death; ex vivo lung perfusion; lung transplantation; organ procurement; transplantation

Mesh:

Year:  2020        PMID: 32563573      PMCID: PMC7647952          DOI: 10.1016/j.jtcvs.2020.04.111

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  24 in total

1.  Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry.

Authors:  Robert S Bonser; Rhiannon Taylor; David Collett; Helen L Thomas; John H Dark; James Neuberger
Journal:  Lancet       Date:  2012-05-29       Impact factor: 79.321

2.  Risk factors for primary graft dysfunction after lung transplantation.

Authors:  Bryan A Whitson; Dilip S Nath; Adam C Johnson; Adam R Walker; Matthew E Prekker; David M Radosevich; Cynthia S Herrington; Peter S Dahlberg
Journal:  J Thorac Cardiovasc Surg       Date:  2005-12-05       Impact factor: 5.209

3.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers.

Authors:  Marc de Perrot; Robert S Bonser; John Dark; Rosemary F Kelly; David McGiffin; Rebecca Menza; Octavio Pajaro; Stephan Schueler; Geert M Verleden
Journal:  J Heart Lung Transplant       Date:  2005-08-08       Impact factor: 10.247

4.  A Multicenter Study on Long-Term Outcomes After Lung Transplantation Comparing Donation After Circulatory Death and Donation After Brain Death.

Authors:  V van Suylen; B Luijk; R A S Hoek; E A van de Graaf; E A Verschuuren; C Van De Wauwer; J A Bekkers; R C A Meijer; W van der Bij; M E Erasmus
Journal:  Am J Transplant       Date:  2017-05-30       Impact factor: 8.086

5.  Excellent clinical outcomes from a national donation-after-determination-of-cardiac-death lung transplant collaborative.

Authors:  B J Levvey; M Harkess; P Hopkins; D Chambers; C Merry; A R Glanville; G I Snell
Journal:  Am J Transplant       Date:  2012-07-23       Impact factor: 8.086

6.  Use of Lung Allografts From Donation After Cardiac Death Donors: A Single-Center Experience.

Authors:  Joseph Costa; Lori Shah; Hilary Robbins; Kashif Raza; Sowmya Sreekandth; Selim Arcasoy; Joshua R Sonett; Frank D'Ovidio
Journal:  Ann Thorac Surg       Date:  2017-11-08       Impact factor: 4.330

7.  Potential suitability for transplantation of hearts from human non-heart-beating donors: data review from the Gift of Life Donor Program.

Authors:  Arun K Singhal; John D Abrams; Jun Mohara; Richard D Hasz; Howard M Nathan; Carol A Fisher; Satoshi Furukawa; Bruce I Goldman
Journal:  J Heart Lung Transplant       Date:  2005-10       Impact factor: 10.247

8.  Should lung transplantation be performed using donation after cardiac death? The United States experience.

Authors:  David P Mason; Lucy Thuita; Joan M Alster; Sudish C Murthy; Marie M Budev; Atul C Mehta; Gösta B Pettersson; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2008-10       Impact factor: 5.209

9.  The potential of cardiac allografts from donors after cardiac death at the University of Wisconsin Organ Procurement Organization.

Authors:  Satoru Osaki; James E Anderson; Maryl R Johnson; Niloo M Edwards; Takushi Kohmoto
Journal:  Eur J Cardiothorac Surg       Date:  2009-08-19       Impact factor: 4.191

10.  Clinical risk factors for primary graft dysfunction after lung transplantation.

Authors:  Joshua M Diamond; James C Lee; Steven M Kawut; Rupal J Shah; A Russell Localio; Scarlett L Bellamy; David J Lederer; Edward Cantu; Benjamin A Kohl; Vibha N Lama; Sangeeta M Bhorade; Maria Crespo; Ejigayehu Demissie; Joshua Sonett; Keith Wille; Jonathan Orens; Ashish S Shah; Ann Weinacker; Selim Arcasoy; Pali D Shah; David S Wilkes; Lorraine B Ware; Scott M Palmer; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2013-01-10       Impact factor: 21.405

View more
  5 in total

1.  Predictors of Older Donor Lung Use: Are We Too Good at Saying No?

Authors:  Ashley Y Choi; Oliver K Jawitz; Vignesh Raman; Samantha E Halpern; John C Haney; Jacob A Klapper; Matthew G Hartwig
Journal:  Ann Thorac Surg       Date:  2020-05-31       Impact factor: 4.330

Review 2.  Ex-vivo lung perfusion therapies: do they add value to organ donation?

Authors:  Amit Lyengar; Alexis Schiazza; Edward Cantu
Journal:  Curr Opin Organ Transplant       Date:  2022-06-01       Impact factor: 2.269

3.  A three-tier system for evaluation of organ procurement organizations' willingness to pursue and utilize nonideal donor lungs.

Authors:  Samantha E Halpern; Alec McConnell; Sarah B Peskoe; Vignesh Raman; Oliver K Jawitz; Ashley Y Choi; Megan L Neely; Scott M Palmer; Matthew G Hartwig
Journal:  Am J Transplant       Date:  2020-10-29       Impact factor: 8.086

Review 4.  Donation after circulatory death donors in lung transplantation.

Authors:  Thomas M Egan; Benjamin E Haithcock; Jason Lobo; Gita Mody; Robert B Love; John Jacob Requard; John Espey; Mir Hasnain Ali
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 3.005

5.  Trends in Donation After Circulatory Death in Lung Transplantation in the United States: Impact Of Era.

Authors:  Christopher M Bobba; Bryan A Whitson; Matthew C Henn; Nahush A Mokadam; Brian C Keller; Justin Rosenheck; Asvin M Ganapathi
Journal:  Transpl Int       Date:  2022-04-04       Impact factor: 3.842

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.